Journal Mobile Options
Table of Contents
Vol. 127, No. 3, 2002
Issue release date: March 2002

Atopic Eczema/Dermatitis Syndrome and Malassezia

Scheynius A. · Johansson C. · Buentke E. · Zargari A. · Tengvall Linder M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Atopic dermatitis is a chronic multifactorial inflammatory skin disease, which has had a marked increase in prevalence during the last decades. Recently, a new nomenclature was recommended where the term ‘atopic eczema/dermatitis syndrome’ (AEDS) should be used to reflect the heterogeneity in this group of patients and where those patients without measurable IgE reactivity should be classified as either ‘nonallergic AEDS’ or ‘non-IgE-associated allergic AEDS’. For nearly 20 years it has been discussed whether the opportunistic yeast Malassezia, previously designated Pityrosporum, is a contributing factor to AEDS. Today there are several reports that demonstrate specific serum IgE or positive skin prick test and/or atopy patch test reactions to Malassezia in patients with AEDS. Several IgE-binding components have been identified in extracts of Malassezia ranging in molecular mass between 10 and 100 kD. The genes for nine Malassezia allergens with molecular weights ranging from 14 to 36 kD have hitherto been identified and cloned. Six of them are now produced by recombinant techniques and used in diagnostic tests. At present the genus Malassezia is subdivided into seven different species, which all have been isolated from human skin. The respective contribution of different Malassezia spp. to AEDS and in what proportion they share allergens remains to be clarified. We summarize here data that Malassezia can play a role in eliciting and maintaining eczema in patients with AEDS.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Rajka G: Essential Aspects of Atopic Dermatitis. Berlin, Springer, 1989.
  2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225–1232.
  3. Alm JS, Swartz J, Lilja G, Scheynius A, Pershagen G: Atopy in children of families with an anthroposophic lifestyle. Lancet 1999;353:1485–1488.
  4. Schultz Larsen F: Atopic dermatitis: A genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993;28:719–723.
  5. Strannegård O, Strannegård IL: The causes of the increasing prevalence of allergy: Is atopy a microbial deprivation disorder? Allergy 2001;56:91–102.
  6. Öhman S, Johansson SGO: Immunoglobulins in atopic dermatitis with special reference to IgE. Acta Derm Venereol 1974;54:193–202.
  7. Werfel T, Kapp A: Environmental and other major provocation factors in atopic dermatitis. Allergy 1998;53:731–739.

    External Resources

  8. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M, Wuthrich B: A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813–824.
  9. Faergemann J: Pityrosporum species as a cause of allergy and infection. Allergy 1999;54:413–419.
  10. Clemmensen O, Hjorth N: Treatment of dermatitis of the head and neck with ketoconazole in patients with type I sensitivity to Pityrosporum orbiculare. Semin Dermatol 1983;2:26–29.
  11. Bäck O, Scheynius A, Johansson SG: Ketoconazole in atopic dermatitis: Therapeutic response is correlated with decrease in serum IgE. Arch Dermatol Res 1995;287:448–451.
  12. Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K: Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001;56:512–517.

    External Resources

  13. Bäck O, Bartosik J: Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2001;15:34–38.
  14. Nordvall SL, Johansson S: IgE antibodies to Pityrosporum orbiculare in children with atopic diseases. Acta Paediatr Scand 1990;79:343–348.
  15. Kieffer M, Bergbrant IM, Faergemann J, Jemec GB, Ottevanger V, Stahl Skov P, Svejgaard E: Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J Am Acad Dermatol 1990;22:739–742.
  16. Rokugo M, Tagami H, Usuba Y, Tomita Y: Contact sensitivity to Pityrosporum ovale in patients with atopic dermatitis. Arch Dermatol 1990;126:627–632.
  17. Wessels MW, Doekes G, van Ieperen-van Kijk AG, Koers WJ, Young E: IgE antibodies to Pityrosporum ovale in atopic dermatitis. Br J Dermatol 1991;125:227–232.
  18. Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM: Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: A comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999;104:1273–1279.
  19. Kim TY, Jang IG, Park YM, Kim HO, Kim CW: Head and neck dermatitis: The role of Malassezia furfur, topical steroid use and environmental factors in its causation. Clin Exp Dermatol 1999;24:226–231.
  20. Mayser P, Gross A: IgE antibodies to Malassezia furfur, M. sympodialis and Pityrosporum orbiculare in patients with atopic dermatitis, seborrheic eczema or pityriasis versicolor, and identification of respective allergens. Acta Derm Venereol 2000;80:357–361.
  21. Tengvall Linder M, Johansson C, Scheynius A, Wahlgren C: Positive atopy patch test reactions to Pityrosporum orbiculare in atopic dermatitis patients. Clin Exp Allergy 2000;30:122–131.
  22. Midgley G: The diversity of Pityrosporum (Malassezia) yeasts in vivo and in vitro. Mycopathologia 1989;106:143–153.
  23. Faergemann J, Aly R, Maibach HI: Quantitative variations in distribution of Pityrosporum orbiculare on clinically normal skin. Acta Derm Venereol 1983;63:346–348.
  24. Faergemann J, Fredriksson T: Age incidence of Pityrosporum orbiculare on human skin. Acta Derm Venereol 1980;60:531–533.

    External Resources

  25. Keddie FM: Electron microscopy of Malassezia furfur in tinea versicolor. Sabouraudia 1966;5:134–137.

    External Resources

  26. Mittag H: Fine structural investigation of Malassezia furfur. II. The envelope of the yeast cells. Mycoses 1995;38:13–21.
  27. Gueho E, Midgley G, Guillot J: The genus Malassezia with description of four new species. Antonie Van Leeuwenhoek 1996;69:337–355.
  28. Eichstedt E: Pilzbildung in der Pityriasis versicolor. Froriep Neue Notizen Geb Naturkunde Heilkunde 1846;39:270–271.
  29. Faergemann J: Tinea versicolor and Pityrosporum orbiculare: Mycological investigations, experimental infections and epidemiological surveys. Acta Derm Venereol Suppl 1979;86:1–23.

    External Resources

  30. Potter BS, Burgoon CF Jr, Johnson WC: Pityrosporum folliculitis. Report of seven cases and review of the Pityrosporum organism relative to cutaneous disease. Arch Dermatol 1973;107:388–391.
  31. Crespo Erchiga V, Ojeda Martos A, Vera Casano A, Crespo Erchiga A, Sanchez Fajardo F: Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol 2000;143:799–803.
  32. Nakabayashi A, Sei Y, Guillot J: Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000;38:337–341.
  33. Gupta AK, Kohli Y, Faergemann J, Summerbell RC: Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. Med Mycol 2001;39:199–206.

    External Resources

  34. Sugita T, Suto H, Unno T, Tsuboi R, Ogawa H, Shinoda T, Nishikawa A: Molecular analysis of Malassezia microflora on the skin of atopic dermatitis patients and healthy subjects. J Clin Microbiol 2001;39:3486–3490.
  35. Arzumanian VG: The yeast Malassezia on the skin of healthy individuals and patients with atopic dermatitis. Vestn Ross Akad Med Nauk 2001;2:29–31.

    External Resources

  36. Sandström MH, Bartosic J, Bäck O, Scheynius A, Särnhult T, Tengvall Linder M, Faergemann J: Förekomst av jästsvampen Malassezia vid atopisk dermatit och seborroisk dermatit. Acta Soc Med Suecanae 2001;110:169.
  37. Johansson S, Karlström K: IgE-binding components in Pityrosporum orbiculare identified by an immunoblotting technique. Acta Derm Venereol 1991;71:11–16.
  38. Zargari A, Härfast B, Johansson S, Johansson SGO, Scheynius A: Identification of allergen components of the opportunistic yeast Pityrosporum orbiculare by monoclonal antibodies. Allergy 1994;49:50–56.
  39. Huang X, Johansson SGO, Zargari A, Nordvall SL: Allergen cross-reactivity between Pityrosporum orbiculare and Candida albicans. Allergy 1995;50:648–656.
  40. Lintu P, Savolainen J, Kalimo K: IgE antibodies to protein and mannan antigens of Pityrosporum ovale in atopic dermatitis patients. Clin Exp Allergy 1997;27:87–95.
  41. Zargari A, Doekes G, van Ieperen-van Dijk AG, Landberg E, Härfast B, Scheynius A: Influence of culture period on the allergenic composition of Pityrosporum orbiculare extracts. Clin Exp Allergy 1995;25:1235–1245.
  42. Zargari A, Eshagi H, Bäck O, Johansson SGO, Scheynius A: Serum IgE reactivity to Malassezia furfur extract and recombinant M. furfur allergens in patients with atopic dermatitis. Acta Derm Venereol, in press.
  43. Johansson C, Eshagi H, Tengvall Linder M, Jakobson E, Scheynius A: Positive atopy patch test reaction to Malassezia furfur in atopic dermatitis correlates with a Th2 like PBMC response. J Invest Dermatol, in press.
  44. Baroni A, Perfetto B, Paoletti I, Ruocco E, Canozo N, Orlando M, Buommino E: Malassezia furfur invasiveness in a keratinocyte cell line (HaCat): Effects on cytoskeleton and on adhesion molecule and cytokine expression. Arch Dermatol Res 2001;293:414–419.
  45. Zargari A, Emilson A, Hallden G, Johansson S, Scheynius A: Cell surface expression of two major yeast allergens in the Pityrosporum genus. Clin Exp Allergy 1997;27:584–592.
  46. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83–93.
  47. Buentke E, Zargari A, Heffler LC, Avila-Carino J, Savolainen J, Scheynius A: Uptake of the yeast Malassezia furfur and its allergenic components by human immature CD1a+ dendritic cells. Clin Exp Allergy 2000;30:1759–1770.

    External Resources

  48. Buentke E, Heffler LC, Wallin RP, Löfman C, Ljunggren HG, Scheynius A: The allergenic yeast Malassezia furfur induces maturation of human dendritic cells. Clin Exp Allergy 2001;31:1583–1593.

    External Resources

  49. Doekes G, Kaal MJ, van Ieperen-van Dijk AG: Allergens of Pityrosporum ovale and Candida albicans. II. Physicochemical characterization. Allergy 1993;48:401–408.

    External Resources

  50. Yoshimoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K: Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948–3953.
  51. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, Paul WE, Nakanishi K: IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 1999;96:13962–13966.
  52. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaka K, Tanaka H, Izumi S, Okamura H, Paul WE, Nakanishi K: IL-18 induction of IgE: Dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000;2:132–137.

    External Resources

  53. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P: Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001;2:882–888.
  54. Albert ML, Jegathesan M, Darnell RB: Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001;2:1010–1017.
  55. Mudde GC, Van Reijsen FC, Boland GJ, de Gast GC, Bruijnzeel PL, Bruijnzeel-Koomen CA: Allergen presentation by epidermal Langerhans’ cells from patients with atopic dermatitis is mediated by IgE. Immunology 1990;69:335–341.
  56. Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285–6290.
  57. Bruynzeel-Koomen C: IgE on Langerhans cells: New insights into the pathogenesis of atopic dermatitis. Dermatologica 1986;172:181–183.

    External Resources

  58. Bruynzeel-Koomen C, van Wichen DF, Toonstra J, Berrens L, Bruynzeel PL: The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 1986;278:199–205.
  59. Bieber T, Dannenberg B, Prinz JC, Rieber EP, Stolz W, Braun-Falco O, Ring J: Occurrence of IgE-bearing epidermal Langerhans cells in atopic eczema: A study of the time course of the lesions and with regard to the IgE serum level. J Invest Dermatol 1989;93:215–219.

    External Resources

  60. Bieber T: IgE-binding molecules on human Langerhans cells. Acta Derm Venereol Suppl 1992;176:54–57.
  61. Langeveld-Wildschut EG, Thepen T, Bihari IC, ven Reijsen FC, de Vries IJ, Bruijnzeel PL, Bruijnzeel-Koomen CA: Evaluation of the atopy patch test and the cutaneous late-phase reaction as relevant models for the study of allergic inflammation in patients with atopic eczema. J Allergy Clin Immunol 1996;98:1019–1027.
  62. Wistokat-Wulfing A, Schmidt P, Darsow U, Ring J, Kapp A, Werfel T: Atopy patch test reactions are associated with T lymphocyte-mediated allergen-specific immune responses in atopic dermatitis. Clin Exp Allergy 1999;29:513–521.
  63. Langeveld-Wildschut EG, Bruijnzeel PL, Mudde GC, Versluis C, van Ieperen-van Dijk AG, Bihari IC, Knol EF, Thepen T, Bruijnzeel-Koomen CA, van Reijsen FC: Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol 2000;105:1008–1016.
  64. Tengvall Linder M, Johansson C, Zargari A, Bengtsson A, van der Ploeg I, Jones I, Härfast B, Scheynius A: Detection of Pityrosporum orbiculare reactive T cells from skin and blood in atopic dermatitis and characterization of their cytokine profiles. Clin Exp Allergy 1996;26:1286–1297.
  65. Tengvall Linder M, Johansson C, Bengtsson A, Holm L, Härfast B, Scheynius A: Pityrosporum orbiculare-reactive T-cell lines in atopic dermatitis patients and healthy individuals. Scand J Immunol 1998;47:152–158.
  66. Savolainen J, Lintu P, Kosonen J, Kortekangas-Savolainen O, Viander M, Pene J, Kalimo K, Terho EO, Bousquet J: Pityrosporum and Candida specific and non-specific humoral, cellular and cytokine responses in atopic dermatitis patients. Clin Exp Allergy 2001;31:125–134.

    External Resources

  67. Kröger S, Neuber K, Gruseck E, Ring J, Abeck D: Pityrosporum ovale extracts increase interleukin-4, interleukin-10 and IgE synthesis in patients with atopic eczema. Acta Derm Venereol 1995;75:357–360.
  68. Leung DY: Atopic dermatitis: New insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860–876.
  69. Bruynzeel-Koomen CA, Van Wichen DF, Spry CJ, Venge P, Bruynzeel PL: Active participation of eosinophils in patch test reactions to inhalant allergens in patients with atopic dermatitis. Br J Dermatol 1988;118:229–238.
  70. Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ: Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 1985;313:282–285.
  71. Kapp A: Atopic dermatitis – The skin manifestation of atopy. Clin Exp Allergy 1995;25:210–219.

    External Resources

  72. van der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML: High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991;97:389–394.
  73. Grewe M, Gyufko K, Schopf E, Krutmann J: Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343:25–26.
  74. Hamid Q, Boguniewicz M, Leung DY: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870–876.
  75. Grewe M, Bruijnzeel-Koomen CA, Schopf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359–361.
  76. Waersted A, Hjorth N: Pityrosporum orbiculare -- A pathogenic factor in atopic dermatitis of the face, scalp and neck? Acta Derm Venereol 1985;114(suppl):146–148.
  77. Broberg A, Faergemann J, Johansson S, Johansson SG, Strannegård IL, Svejgaard E: Pityrosporum ovale and atopic dermatitis in children and young adults. Acta Derm Venereol 1992;72:187–192.
  78. Lindgren L, Wahlgren CF, Johansson SG, Wiklund I, Nordvall SL: Occurrence and clinical features of sensitization to Pityrosporum orbiculare and other allergens in children with atopic dermatitis. Acta Derm Venereol 1995;75:300–304.
  79. Koyama T, Kanbe T, Ishiguro A, Kikuchi A, Tomita Y: Antigenic components of Malassezia species for immunoglobulin E antibodies in sera of patients with atopic dermatitis. J Dermatol Sci 2001;26:201–208.

    External Resources

  80. Faergemann J: Antibodies to Pityrosporum orbiculare in patients with tinea versicolor and controls of various ages. J Invest Dermatol 1983;80:133–135.
  81. Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TA: Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982;i:127–130.
  82. Taieb A, Ducombs G: Aeroallergen contact dermatitis. Clin Rev Allergy Immunol 1996;14:209–223.
  83. Darsow U, Ring J: Airborne and dietary allergens in atopic eczema: A comprehensive review of diagnostic tests. Clin Exp Dermatol 2000;25:544–551.

    External Resources

  84. Johansson C, Sandström MH, Bartosik J, Särnhult T, Christiansen J, Zargari A, Bäck O, Wahlgren CF, Faergemann J, Scheynius A, Tengvall Linder M: Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients. Submitted.
  85. Günther S, Reiser K, Darsow U, Wollenberg A: Demonstration of clinically relevant sensitization of house dust mite allergen in prick and RAST negative atopic dermatitis patients with the atopy patch test. J Invest Dermatol 2001;117:816.

    External Resources

  86. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B: Epidemiology, clinical features, and immunology of the ‘intrinsic’ (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001;56:841–849.

    External Resources

  87. Valenta R, Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WW, Twardosz A, Barletta B, Becker WM, Blaser K, Breiteneder H, Chapman M, Crameri R, Duchene M, Ferreira F, Fiebig H, Hoffmann-Sommergruber K, King TP, Kleber-Janke T, Kurup VP, Lehrer SB, Lidholm J, Muller U, Pini C, Reese G, Scheiner O, Scheynius A, Shen H-D, Spitzauer S, Suck R, Swoboda I, Thomas W, Tinghino R, van Hage-Hamsten M, Virtanen T, Kraft D: Microarrayed allergen molecules: Diagnostic gatekeepers for allergy treatment. FASEB J, in press.
  88. Robin C: Histoire naturelle des végétaux parasites. Paris, Baillère, 1853, p 438.
  89. Baillon H: Traité de botanique médicale cryptogamique. Paris, Octave Doin, 1889, pp 234–239.
  90. Sabouraud R: Les maladies desquamatives: pityriasis et alopécies pelliculaires. Maladies du cuir chevelu. Paris, Masson, 1904.
  91. Castellani A, Chalmers AJ: Manual of tropical medicine. London, Baillière, Tindall & Cox, 1913, p 1747.
  92. Weidman FD: Exfoliative dermatitis in the Indian rhinoceros (Rhinoceros unicornis), with description of a new yeast species, Pityrosporum pachydermatis; in: Fox H (ed). Philadelphia, 1925, p 43.
  93. Gordon MA: Lipophilic yeast-like organisms associated with tinea versicolor. J Invest Dermatol 1951;17:267–272.
  94. Ranjandiche M: Polymorphism of Pityrosporum ovale (Bizzozero) Castellani and Chalmers in vivo and in vitro. Bull Soc Fr Mycol Med 1976;5:79–82.
  95. Faergemann J, Tjernlund U, Scheynius A, Bernander S: Antigenic similarities and differences in genus Pityrosporum. J Invest Dermatol 1982;78:28–31.

    External Resources

  96. Yarrow D, Ahearn DG: Genus 7: Malassezia Baillon. Amsterdam, Elsevier Scientific Publisher, 1984, pp 882–885.
  97. Gueho E, Meyer SA: A reevaluation of the genus Malassezia by means of genome comparison. Antonie Van Leeuwenhoek 1989;55:245–251.
  98. Cunningham AC, Leeming JP, Ingham E, Gowland G: Differentiation of three serovars of Malassezia furfur. J Appl Bacteriol 1990;68:439–446.
  99. Simmons RB, Gueho E: A new species of Malassezia. Mycol Res 1990;94:1146–1149.
  100. Guillot J, Gueho E: The diversity of Malassezia yeasts confirmed by rRNA sequence and nuclear DNA comparisons. Antonie Van Leeuwenhoek 1995;67:297–314.
  101. Schmidt M, Zargari A, Holt P, Lindbom L, Hellman U, Whitley P, van der Ploeg I, Härfast B, Scheynius A: The complete cDNA sequence and expression of the first major allergenic protein of Malassezia furfur, Mal f 1. Eur J Biochem 1997;246:181–185.
  102. Yasueda H, Hashida-Okado T, Saito A, Uchida K, Kuroda M, Onishi Y, Takahashi K, Yamaguchi H, Takesako K, Akiyama K: Identification and cloning of two novel allergens from the lipophilic yeast, Malassezia furfur. Biochem Biophys Res Commun 1998;248:240–244.
  103. Onishi Y, Kuroda M, Yasueda H, Saito A, Sono-Koyama E, Tunasawa S, Hashida-Okado T, Yagihara T, Uchida K, Yamaguchi H, Akiyama K, Kato I, Takesako K: Two-dimensional electrophoresis of Malassezia allergens for atopic dermatitis and isolation of Mal f 4 homologs with mitochondrial malate dehydrogenase. Eur J Biochem 1999;261:148–154.
  104. Lindborg M, Magnusson CG, Zargari A, Schmidt M, Scheynius A, Crameri R, Whitley P: Selective cloning of allergens from the skin colonizing yeast Malassezia furfur by phage surface display technology. J Invest Dermatol 1999;113:156–161.
  105. Rasool O, Zargari A, Almqvist J, Eshaghi H, Whitley P, Scheynius A: Cloning, characterization and expression of complete coding sequences of three IgE binding Malassezia furfur allergens, Mal f 7, Mal f 8 and Mal f 9. Eur J Biochem 2000;267:4355–4361.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50